Effects of Magnesium Carbonate tablet on hyperphosphatemia in patients under hemodialysis

Evaluation of effectiveness and safety of Magnesium Carbonate and comparison with calcium carbonate in hyperphosphatemic end stage renal disease patients on chronic hemodialysis.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201105186515N1

Enrollment

Registered

2011-07-02

Start date

2010-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: End stage renal disease. Condition 2: hyperphosphatemia. End Stage Renal Disease classified in other phosphoru metabolism defect.

Interventions

Intervention 1: Control group: 25 ESRD patients on hemodialysis with serum phosphorus > 5.5 mg/dl will use CaCo3 500 mg trice daily with meal if 6.5>P>5.5 one Tablet if 7.5>P>6.5 two tablet will be ad

Treatment - Drugs

Control group: 25 ESRD patients on hemodialysis with serum phosphorus > 5.5 mg/dl will use CaCo3 500 mg trice daily with meal if 6.5>P>5.5 one Tablet if 7.5>P>6.5 two tablet will be added and if P> 7.

Intervention group: 25 ESRD patients on hemodialysis with serum phosphorus > 5.5 mg/dl will use MgCo3 250 mg trice daily with meal if 6.5>P>5.5 one Tablet if 7.5>P>6.5 two tablet and if P> 7.5 thr

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age>18 years; serum phosphorus >5.5 mg/dl; at least 3 months on hemodialysis. exclusion criteria: serum magnesium > 4 mg/dl; pregnancy; previous parathyroidectomy; sever hyperparathyroidism(iPTH> 500 pg/ml); Medical disease cause diarrhea; Kidney transplant; Patient Death; Non-compliance of drug usage (at least 80% of prescribed drug must be used); Drug complications making the patient unable to continue the treatment; Lost hemodialysis more than one per month or Irregular hemodialysis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Changes in serum phosphorus level. Timepoint: Before trial and every 2 weeks till at the end of 6the week. Method of measurement: Lab data mg/dl.;Changes in Ca X P product. Timepoint: Before trial then every 2 weeks till the end of 6th week. Method of measurement: Lab data mg/dl.;Changes in serum calcium. Timepoint: Before trial and every two weeks till the end of 6th week. Method of measurement: Lab data mg/dl.;Changes in serum magnesium. Timepoint: Before trial and every two weeks till the end of 6th week. Method of measurement: Lab data, mg/dl.	—

Measure

Time frame

Changes in serum phosphorus level. Timepoint: Before trial and every 2 weeks till at the end of 6the week. Method of measurement: Lab data mg/dl.;Changes in Ca X P product. Timepoint: Before trial then every 2 weeks till the end of 6th week. Method of measurement: Lab data mg/dl.;Changes in serum calcium. Timepoint: Before trial and every two weeks till the end of 6th week. Method of measurement: Lab data mg/dl.;Changes in serum magnesium. Timepoint: Before trial and every two weeks till the end of 6th week. Method of measurement: Lab data, mg/dl.

—

Secondary

Measure	Time frame
Abdominal pain and diarrhea. Timepoint: Before trial then every 2 weeks till the end of 6th week. Method of measurement: Clinical data(history and examination).;Cardiac arhrythmia. Timepoint: Before trial then every 2 weeks till the end of 6th week. Method of measurement: Clinical data(history and examination) and electrocardiography.;Serum LDL, HDL, Tg, Chol,. Timepoint: Before trial then at the end of 6th week. Method of measurement: Lab data mg/dl.;PTH. Timepoint: Before trial then at the end of 6th week. Method of measurement: Lab data pg/ml.;CRP. Timepoint: before trial then every 2 weeks till the end of 6th week. Method of measurement: lab data mg/l.;Serum HCo3. Timepoint: Before trial then every 2 weeks till the end of 6th week. Method of measurement: Lab data mmol/l.;Blood pressure. Timepoint: Before trial then every 2 weeks till the end of 6th week. Method of measurement: Clinical data(examination) mmHg.	—

Measure

Time frame

Abdominal pain and diarrhea. Timepoint: Before trial then every 2 weeks till the end of 6th week. Method of measurement: Clinical data(history and examination).;Cardiac arhrythmia. Timepoint: Before trial then every 2 weeks till the end of 6th week. Method of measurement: Clinical data(history and examination) and electrocardiography.;Serum LDL, HDL, Tg, Chol,. Timepoint: Before trial then at the end of 6th week. Method of measurement: Lab data mg/dl.;PTH. Timepoint: Before trial then at the end of 6th week. Method of measurement: Lab data pg/ml.;CRP. Timepoint: before trial then every 2 weeks till the end of 6th week. Method of measurement: lab data mg/l.;Serum HCo3. Timepoint: Before trial then every 2 weeks till the end of 6th week. Method of measurement: Lab data mmol/l.;Blood pressure. Timepoint: Before trial then every 2 weeks till the end of 6th week. Method of measurement: Clinical data(examination) mmHg.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shahrzad Shahidi

Isfahan University of Medical Sciences

research@mui.ac.ir+98 31 1668 5149

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026